je.st
news
How RBC Capital Called A 50% Gain In This Biotech Stock
2015-04-02 14:18:31| Biotech - Topix.net
Shares of Dyax Corp. closed up more than 53 percent on Wednesday after the company announced positive results from an early-stage test of its drug DX-2930 on treatment of Hereditary Angioedema . Benzinga had the chance to speak with Dyax's Executive Vice President of R&D, Dr. Burt Adelman, about what the results mean for the company.
Tags: this
called
stock
capital
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||